Xian G. Zhang
Langfang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Efficacy, Safety, and Kinetics of Naturally Selected Anti-CD7 CAR-T Cell Therapy in T-ALL/LBL With CNS Leukemia.
Journal: American journal of hematology
Published: April 17, 2026
Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 16, 2026
CD72 as a complementary B-lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR-T therapy in R/R B-ALL.
Journal: Cytometry. Part B, Clinical cytometry
Published: March 10, 2026
Metabolomic Profiling and Machine Learning-Based Prediction of High-Dose Methotrexate-Induced Liver Injury in Pediatric Acute Lymphoblastic Leukemia.
Journal: Pediatric blood & cancer
Published: December 23, 2025
Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
Journal: British journal of haematology
Published: June 19, 2025
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma.
Journal: Blood advances
Published: February 26, 2025
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia.
Journal: Blood
Published: April 01, 2024
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
Journal: British journal of haematology
Published: January 25, 2024
Last Updated: 09/26/2026